Supercharge Your Innovation With Domain-Expert AI Agents!

Compositions and methods for the treatment of cancer

一种化合物、卤化物的技术，应用在化学仪器和方法、药物组合、铂类有机化合物等方向，能够解决限制应用等问题

Inactive Publication Date: 2014-07-09
MASSACHUSETTS INST OF TECH +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, carboplatin has the advantage of being less harmful to the kidneys, but its cross-resistance to cisplatin limits its use in otherwise cisplatin-treatable diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for the treatment of cancer
  • Compositions and methods for the treatment of cancer
  • Compositions and methods for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0202] This example describes the synthesis and use of phenanthroplatin (eg, a compound of formula (VII)).

[0203] Experiment Details

[0204] materials and measurements. Picoplatin was synthesized as previously reported (J. Med. Chem. 1989, 32, 128-136). All other chemicals and solvents are commercially available. Recorded on a Bruker AVANCE-400 NMR spectrometer with a spectrally rotating superconducting magnet at the Massachusetts Institute of Technology Department of Chemistry Instrumentation Facility (MIT DCIF) 1 H. 13 C and 195 Pt NMR spectrum. Chemical shift for 195 Pt NMR reference in D 2 K in O 2 PtCl 4 (δ=-1628ppm) or for 1 H and 13 C NMR referenced to residual solvent peak. ESI-MS spectra were acquired on an Agilent Technologies 1100 Series LC / MS instrument. Atomic absorption spectroscopy was performed on a Perkin Elmer AAnalyst300 spectrometer. Distilled water was purified by passing through a Milli-Q Biocel water purification system (18.2 MΩ) with a ...

example 2

[0251] This example concerns the determination of the maximum tolerated dose (MTD) of phenanthroplatin in mice. The maximum tolerated dose (MTD) is defined as the highest dose of a drug or treatment that does not cause any adverse side effects. This example describes the determination of the MTD of phenoplatin administered intravenously to albino ICR mice.

[0252] Experimental part

[0253] animal. In this study, 42 healthy albino ICR female mice (19.9–28.7 g weight) were used.

[0254]Detailed process. In Phase 1 of the study, 12 ICR albino mice were assigned to receive 4 different concentrations of phenanthplatin via tail vein injection (Table 7). Three additional mice were dosed with PBS as vehicle controls. In Phase 2 of the study, 24 ICR albino mice were assigned to receive 8 different concentrations of phenanthplatin via tail vein injection (Table 8). Three additional mice were dosed with PBS as vehicle controls. Mice were observed for side effects immediately af...

example 3

[0269] This example describes the encapsulation of phenanthrene platinum into polymeric nanoparticles by using the double emulsion method with PLGA-PEG-COOH and the nanoprecipitation method with functionalized PLA-OH and PLGA-PEG-COOH.

[0270] Experimental part

[0271] Materials and Measurements. Synthesis of phenanthroplatin was performed as previously described. All chemicals and solvents are commercially available. Recorded on a Bruker AVANCE-400 NMR spectrometer with a spectrally rotating superconducting magnet at the Massachusetts Institute of Technology Department of Chemistry Instrumentation Facility (MIT DCIF) 1 H. 13 C and 195 Pt NMR spectra. Electrospray ionization-MS (ESI-MS) spectra were acquired on an Agilent Technologies 1100 Series LC / MS instrument. Atomic absorption spectroscopy was performed on a Perkin Elmer AAnalyst600 spectrometer. Elemental analyzes were performed by Midwest Microlab, LLC, Indianapolis, IN. Distilled water was purified by passing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.

Description

[0001] Statement Regarding Federally Sponsored Research or Development [0002] This invention was made with Government support under Grant No. R01 CA034992 awarded by the National Institutes of Health. The Government has certain rights in this invention. field of invention [0003] The present invention relates to compositions, kits and methods for treating cancer. In some cases, the composition includes a platinum compound that includes a phenanthridine ligand. Background of the invention [0004] Platinum-based drugs are among the most active and widely used anticancer agents and cisplatin represents one of three FDA-approved, platinum-based cancer chemotherapy drugs. Although cisplatin is effective against a variety of solid tumors, especially testicular and ovarian cancers, its clinical use is limited due to its toxic effects coupled with intrinsic and acquired resistance of some tumors to this class of drugs . To overcome these limitations, platinum analogs with lo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/51C07F15/00A61K33/24A61P35/00
CPCA61P35/00C07F15/0093A61K9/1629A61K9/1641A61K47/56A61K47/60A61K47/6921A61K33/243
Inventor S·J·利帕德G·Y·朴T·约翰斯通O·C·法罗克扎德S·加德
Owner MASSACHUSETTS INST OF TECH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com